INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 428m ago
HOUSE PTR27m ago
SEC 13F27m ago
ROBINHOOD CHAIN27m ago
Public company

OKUROnKure Therapeutics, Inc.

CIK 0001637715

EDGAR filingsOpen in network
Disclosed transactions15
Buys / sells0 / 2
Max Insider Score26
Connections7with evidence

OKUR · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
26
LA
Leverone Jason A.Chief Financial Officer
OKUROnKure Therapeutics, Inc.
Open-market sale
SELL$898
302 sh
Sep 21, 2026Sep 23, 2026
traded Sep 21, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Insider ofevidence
    Leverone Jason A.Chief Financial Officer · Sep 23, 2026
  • ← Insider ofevidence
    Saccomano Nicholas ADirector, President and CEO · Sep 23, 2026
  • ← Insider ofevidence
    Agresta SamuelChief Medical Officer · Aug 11, 2026
26
SA
Saccomano Nicholas ADirector, President and CEO
OKUROnKure Therapeutics, Inc.
Open-market sale
SELL
$259
87 sh
Sep 21, 2026
Sep 23, 2026
traded Sep 21, 2026
+2d
SEC FORM 4

Evidence

9
AS
Agresta SamuelChief Medical Officer
OKUROnKure Therapeutics, Inc.
Grant or award
A—
18.6K sh
Aug 7, 2026Aug 11, 2026
traded Aug 7, 2026
+4dSEC FORM 4

Evidence

9
AS
Agresta SamuelChief Medical Officer
OKUROnKure Therapeutics, Inc.
Disposition to issuer
D—
131.4K sh
Aug 7, 2026Aug 11, 2026
traded Aug 7, 2026
+4dSEC FORM 4

Evidence

9
AS
Agresta SamuelChief Medical Officer
OKUROnKure Therapeutics, Inc.
Grant or award
A—
50.0K sh
Aug 7, 2026Aug 11, 2026
traded Aug 7, 2026
+4dSEC FORM 4

Evidence

9
AS
Agresta SamuelChief Medical Officer
OKUROnKure Therapeutics, Inc.
Grant or award
A—
131.4K sh
Aug 7, 2026Aug 11, 2026
traded Aug 7, 2026
+4dSEC FORM 4

Evidence

9
JM
Jansen Valerie MalyvanhDirector
OKUROnKure Therapeutics, Inc.
Grant or award
A—
22.4K sh
Aug 7, 2026Aug 11, 2026
traded Aug 7, 2026
+4dSEC FORM 4

Evidence

9
HD
Hartley DylanChief Scientific Officer
OKUROnKure Therapeutics, Inc.
Grant or award
A—
50.0K sh
Aug 7, 2026Aug 11, 2026
traded Aug 7, 2026
+4dSEC FORM 4

Evidence

9
HD
Hartley DylanChief Scientific Officer
OKUROnKure Therapeutics, Inc.
Disposition to issuer
D—
137.6K sh
Aug 7, 2026Aug 11, 2026
traded Aug 7, 2026
+4dSEC FORM 4

Evidence

9
HD
Hartley DylanChief Scientific Officer
OKUROnKure Therapeutics, Inc.
Grant or award
A—
137.6K sh
Aug 7, 2026Aug 11, 2026
traded Aug 7, 2026
+4dSEC FORM 4

Evidence

9
PJ
Phillips Andrew JohnDirector
OKUROnKure Therapeutics, Inc.
Grant or award
A—
22.4K sh
Aug 7, 2026Aug 11, 2026
traded Aug 7, 2026
+4dSEC FORM 4

Evidence

9
AS
Agresta SamuelChief Medical Officer
OKUROnKure Therapeutics, Inc.
Disposition to issuer
D—
18.6K sh
Aug 7, 2026Aug 11, 2026
traded Aug 7, 2026
+4dSEC FORM 4

Evidence

9
JM
Jansen Valerie MalyvanhDirector
OKUROnKure Therapeutics, Inc.
Grant or award
A—
7,650 sh
Jun 4, 2026Jun 8, 2026
traded Jun 4, 2026
+4dSEC FORM 4

Evidence

9
PJ
Phillips Andrew JohnDirector
OKUROnKure Therapeutics, Inc.
Grant or award
A—
7,650 sh
Jun 4, 2026Jun 8, 2026
traded Jun 4, 2026
+4dSEC FORM 4

Evidence

9
HD
Hartley DylanChief Scientific Officer
OKUROnKure Therapeutics, Inc.
Grant or award
A—
110.0K sh
Apr 1, 2026Apr 3, 2026
traded Apr 1, 2026
+2dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Jansen Valerie MalyvanhDirector · Jun 8, 2026
  • ← Insider ofevidence
    Phillips Andrew JohnDirector · Jun 8, 2026
  • ← Insider ofevidence
    Hartley DylanChief Scientific Officer · Apr 3, 2026